newsfilter
← Latest News
GlobeNewswire·

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation